Performance of enhanced liver fibrosis plasma markers in asymptomatic individuals with ZZ α1-antitrypsin deficiency

European Journal of Gastroenterology and Hepatology

Volumn 23, Issue 8, 2011, Pages 716-720

  Janciauskiene, Sabina ^a   Wallmark, Anders ^b   Piitulainen, Eeva ^b   Köhnlein, Thomas ^a   Welte, Tobias ^a   Sveger, Tomas ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

alpha 1 antitrypsin deficiency; enhanced liver fibrosis; liver disease; plasma markers

Indexed keywords

ALPHA 1 ANTITRYPSIN; COLLAGEN TYPE 3; HYALURONIC ACID; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE;

ADULT; AGE; ALPHA 1 ANTITRYPSIN DEFICIENCY; AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENETIC VARIABILITY; HUMAN; HUMAN EXPERIMENT; LIVER FIBROSIS; LIVER NECROSIS; LOGISTIC REGRESSION ANALYSIS; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RISK; SENSITIVITY AND SPECIFICITY; SWEDEN;

ADULT; ALPHA 1-ANTITRYPSIN DEFICIENCY; APOPTOSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COLLAGEN TYPE III; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; HYALURONIC ACID; LIVER; LIVER CIRRHOSIS; MALE; NECROSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 79960698421     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328347daaf     Document Type: Article

References (39)

1. Kohnlein T, Welte T. Alpha-1 antitrypsin deficiency: pathogenesis, clinical presentation, diagnosis, and treatment. Am J Med 2008; 121:3-9.
2. Janciauskiene S. Conformational properties of serine proteinase inhibitors (serpins) confer multiple pathophysiological roles. Biochim Biophys Acta 2001; 1535:221-235. (Pubitemid 32241132)
3. Carrell RW, Lomas DA. Alpha-1-antitrypsin deficiency: a model for conformational diseases. N Engl J Med 2002; 346:45-53. (Pubitemid 34438920)
4. Janciauskiene S, Eriksson S, Callea F, Mallya M, Zhou A, Seyama K, et al. Differential detection of PAS-positive inclusions formed by the Z, Siiyama, and Mmalton variants of alpha1-antitrypsin. Hepatology 2004; 40:1203-1210. (Pubitemid 39425577)
5. Hidvegi T, Ewing M, Hale P, Dippold C, Beckett C, Kemp C, et al. An autophagy-enhancing drug promotes degradation of mutant alpha1- antitrypsin Z and reduces hepatic fibrosis. Science 2010; 229-232.
6. Fairbanks KD, Tavill AS. Liver disease in alpha 1-antitrypsin deficiency: a review. Am J Gastroenterol 2008; 103:2136-2141.
7. Perlmutter DH, Brodsky JL, Balistreri WF, Trapnell BC. Molecular pathogenesis of alpha-1-antitrypsin deficiency-associated liver disease: a meeting review. Hepatology 2007; 45:1313-1323. (Pubitemid 46775796)
8. Wu Y, Termine DJ, Swulius MT, Moremen KW, Sifers RN. Human endoplasmic reticulum mannosidase I is subject to regulated proteolysis. J Biol Chem 2007; 282:4841-4849. (Pubitemid 47100935)
9. Avezov E, Frenkel Z, Ehrlich M, Herscovics A, Lederkremer GZ. Endoplasmic reticulum (ER) mannosidase I is compartmentalized and required for N-glycan trimming to Man5-6GlcNAc2 in glycoprotein ERassociated degradation. Mol Biol Cell 2008; 19:216-225. (Pubitemid 351186147)
10. Pan S, Huang L, McPherson J, Muzny D, Rouhani F, Brantly M, et al. Single nucleotide polymorphism-mediated translational suppression of endoplasmic reticulum mannosidase I modifies the onset of end-stage liver disease in alpha1-antitrypsin deficiency. Hepatology 2009; 50:275-281.
11. Primhak RA, Tanner MS. Alpha-1-antitrypsin deficiency. Arch Dis Child 2001; 85:2-5.
12. Sveger T, Eriksson S. The liver in adolescents with a1-antitrypsin deficiency. Hepatology 1995; 22:514-517.
13. Nebbia G, Hadchouel M, Odievre M, Alagille D. Early assessment of evolution of liver disease associated with a1-antitrypsin deficiency in childhood. J Pediatr 1983; 102:661-665. (Pubitemid 13089390)
14. Filipponi F, Soubrane O, Labrousse F, Devictor D, Bernard O, Valayer J, Houssin D. Liver transplantation for end-stage liver disease associated with a1-antitrypsin deficiency in children: pretransplant natural history, timing and results of transplantation. J Hepatol 1994; 20:72-78. (Pubitemid 24043088)
15. Francavilla R, Castellaneta SP, Hadzic N. Prognosis of a1-antitrypsin deficiency-related liver disease in the era of pediatric liver transplantation. J Hepatol 2000; 32:986-992. (Pubitemid 30368092)
16. Fleming LE, Oquendo S, Bean JA, Tamer R, Finn S, Wanner A, et al. Pilot deficiency study of alpha 1 antitrypsin deficiency in targeted population. Am J Med Genet 2001; 103:69-74.
17. Sveger T. Liver disease in alpha-1-antitrypsin deficiency detected by screening of 200 000 infants. N Engl J Med 1976; 24:1316-1321.
18. Piitulainen E, Carlson J, Ohlsson K, Sveger T. Alpha1-antitrypsin deficiency in 26-year-old subjects: lung, liver, and protease/protease inhibitor studies. Chest 2005; 128:2076-2081. (Pubitemid 41507543)
19. Bernspång E, Carlson J, Piitulainen E. The liver in 30-year-old individuals with alpha(1)-antitrypsin deficiency. Scand J Gastroenterol 2009; 44:1349-1355.
20. Eriksson S, Carlson J, Velez R. Risk of cirrhosis and primary liver cancer in alpha1-antitrypsin deficiency. N Engl J Med 1986; 314:736-739. (Pubitemid 16124387)
21. Parkes J, Roderick P, Harris S, Day C, Mutimer D, Collier J, et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010; 59:1245-1251.
22. Parkes J, Guha IN, Roderick P, Harris S, Cross R, Manos MM, et al. Enhanced liver fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. J Viral Hepat 2010 [Epub ahead of print]
23. Leers MP, Kölgen W, Björklund V, Bergman T, Tribbick G, Persson B, et al. Immunocytochemical detection and mapping of a cytokeratin 18 neoepitope exposed during early apoptosis. J Pathol 1999; 187:567-572. (Pubitemid 29151999)
24. Kramer G, Erdal H, Mertens HJ, Nap M, Mauermann J, Steiner G, et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 2004; 64:1751-1756. (Pubitemid 38428698)
25. Kalsheker NA. Alpha1-antitrypsin deficiency: best clinical practice. J Clin Pathol 2009; 62:865-869.
26. Francalanci P, Santorelli FM, Saccani S, Bonetti MF, Medicina D, Coni P, et al. Z and Mmalton-1-antitrypsin deficiency-associated hepatocellular carcinoma: a genetic study. Liver Int 2009; 29:1593-1596.
27. Ellis G, Goldberg DM, Spooner RJ, Ward AM. Serum enzyme tests in diseases of the liver and biliary tree. Am J Clin Pathol 1978; 70:248-258. (Pubitemid 9005446)
28. Kahraman A, Schlattjan M, Kocabayoglu P, Yildiz-Meziletoglu S, Schlensak M, Fingas CD, et al. histocompatibility complex class I-related chains A and B (MIC A/B): a novel role in nonalcoholic steatohepatitis. Hepatology 2010; 51:92-102.
29. Pinzani M. The ELF panel: a new crystal ball in hepatology? Gut 2010; 59:1165-1167.
30. Nobili V, Parkes J, Bottazzo G, Marcellini M, Cross R, Newman D, et al. Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology 2009; 136:160-167.
31. Eriksson S, Sveger T. Procollagen type III peptide in asymptomatic children with alpha 1-antitrypsin deficiency. J Pediatr Gastroenterol Nutr 1988; 7:938-939.
32. Teckman JH, Perlmutter DH. Retention of mutant alpha-1 antitripsyn Z in endoplasmic reticulum is associated with an autophagic response. Am J Physiol Gasterointest Liver Physiol 2000; 279:G961-G974.
33. Perlmutter DH. Liver injury in a1-antitripsyn deficiency: an aggregated protein induces mitochondrial injury. J Clin Invest 2002; 110:1579-1583. (Pubitemid 35424232)
34. Greene CM, McElvaney NG. Z a-1 antitrypsin deficiency and the endoplasmic reticulum stress response. World J Gastrointest Pharmacol Ther 2010; 1:94-101.
35. Rudnick DA, Perlmutter DH. Alpha-1-antitrypsin deficiency: a new paradigm for hepatocellular carcinoma in genetic liver disease. Hepatology 2005; 42:514-521. (Pubitemid 41233640)
36. Rudnick DA, Liao Y, An JK, Muglia LJ, Perlmutter DH, Teckman JH. Analyses of hepatocellular proliferation in a mouse model of alpha-1-antitrypsin deficiency. Hepatology 2004; 39:1048-1055. (Pubitemid 38428944)
37. Schutte B, Henfling M, Kölgen W, Bouman M, Meex S, Leers MP, et al. Keratin 8/18 breakdown and reorganization during apoptosis. Exp Cell Res 2004; 297:11-26. (Pubitemid 38759558)
38. Fitzpatrick E, Mitry RR, Quaglia A, Hussain MJ, DeBruyne R, Dhawan A. Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD. J Pediatr Gastroenterol Nutr 2010; 51:500-506.
39. Bechmann LP, Marquitan G, Jochum C, Saner F, Gerken G, Canbay A. Apoptosis versus necrosis rate as a predictor in acute liver failure following acetaminophen intoxication compared with acute-on-chronic liver failure. Liver Int 2008; 28:713-716. (Pubitemid 351541105)